Wire · operational-macro
IntraBio Announces U.S. FDA Approval of AQNEURSA® (levacetylleucine) for Ataxia-Telangiectasia
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
The U.S. FDA has approved AQNEURSA® (levacetylleucine) for treating ataxia in patients with ataxia-telangiectasia (A-T), marking the first-ever approved treatment for this rare neurodegenerative disease. This approval follows AQNEURSA's earlier FDA clearance for Niemann-Pick disease type C, providing a new therapeutic option now commercially available.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You gain access to a treatment market previously untapped by any FDA-approved drug, which means urgent opportunities in patient outreach and rare disease care partnerships now exist.
◆ Coverage
4 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics